RE:FDA guides on how AA can be converted to full approval.So when Matt stated that the trial design for the breast cancer Phase 3 clinical trial would include 200-300 patients - he would seem to have been informing us that ..the trial sample size would be large enough to adequately power the detection of a clinically meaningful and statistically significant improvement in both the endpoints for accelerated approval (e.g., response rate) and verification of clinical benefit (e.g., PFS or OS) - as the FDA pointed out in its draft guidance released today.